REG - Abingdon Health PLC - Director/PDMR Shareholding

Abingdon HealthAnnouncement

16/09/2022 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220916:nRSP8177Za&default-theme=true

RNS Number : 8177Z  Abingdon Health PLC  16 September 2022

Abingdon Health plc

("Abingdon" or "the Company")

 

Director/PDMR Dealing

 

York, U.K. 16 September 2022: Abingdon Health plc (AIM: ABDX), a leading
international developer and manufacturer of high quality and effective rapid
tests, announces that between 14 and 16 September 2022, Chris Yates, Chief
Executive Officer and Dr Christopher Hand, Chairman, purchased a total of
250,000 and 800,000 ordinary shares of 0.25 pence each ("Ordinary Shares")
respectively over a series of trades (the "Purchases").

 

The weighted average price of the shares Purchased by Dr Christopher Hand and
Chris Yates was 6.338 pence and 6.274 pence per Ordinary Share respectively.
Further to these transactions, the interests of the two directors are as
follows:

 

 Director             Previous number of Ordinary Shares held  Number of Ordinary Shares Purchased  Number of Ordinary Shares held following Purchases  Percentage of Ordinary Shares held following Purchases
 Dr Christopher Hand  12,228,467                               800,000                              13,028,467                                          10.7%
 Chris Yates          7,513,844                                250,000                              7,763,844                                           6.4%

 

Concert Party

 

Further to the disclosures in the Company's Admission Document published 11
December 2020 ("Admission Document"), both Dr Christopher Hand and Christopher
Yates are members of a concert party (the "Concert Party"). As a result of the
Purchases, the aggregate number of Ordinary Shares held by the Concert Party
has increased from 41,811,888 to 42,861,888, representing an increase from
34.35 per cent. to 35.21 per cent. of the issued share capital of the Company.

 

The Purchases were effected under the terms of Note 11 on Rule 9.1 of the Code
and therefore have no consequences under the Takeover Code.

 

As set out in the Company's Admission Document, Chris Yates also holds 392,695
options over Ordinary Shares. It was agreed with the Panel prior to the
Company's initial public offering that an obligation under Rule 9 will not
arise as a result of the issue of new Ordinary Shares to members of the
Concert Party following the exercise of those options referred to above,
without the requirement to seek the approval of independent shareholders.

 

The Concert Party could therefore come to hold in aggregate up to 43,254,513
Ordinary Shares (following the exercise of all options held by its members
only), representing a maximum potential interest of up to 35.42 per cent. of
the enlarged share capital (as enlarged by such exercise).

 

Details of the transactions undertaken can be found in the Notification of
Dealing Form below.

Enquiries:

 

 Abingdon Health plc                                                                   www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                                  Via Walbrook PR
 Melanie Ross, Chief Financial Officer
 Dr Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)                            Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond, Sam Butcher (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 Walbrook PR Limited                                      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                                          (mailto:abingdon@walbrookpr.com)
 Phillip Marriage / Alice Woodings  Mob: +44 (0)7867 984 082 / +44 (0)7407 804 654

 

 

 

 

About Abingdon Health plc

 

Abingdon Health is a world leading developer and manufacturer of
high-quality lateral flow rapid tests
(https://www.abingdonhealth.com/services/)  across all industry sectors,
including healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial concept through
to routine and large-scale manufacturing and has also developed and marketed
its own labelled tests.

 

The Company offers product development, regulatory support, technology
transfer and manufacturing services for customers looking to develop new
assays or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes. This ability has a significant role to play in improving life across
the world. To support this aim Abingdon Health has also developed AppDx(®),
a customisable image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of
this announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Chris Yates

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Abingdon Health plc

 b)   LEI                                                          213800XFI4WV3FBILO20

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.025 pence each

      Identification code                                          GB00BLF79J41

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)                          Volume(s)
                                                                                     5.89 pence                        50,933
                                                                                     5.9499 pence                      50,000
                                                                                     6.35 pence                        10,000
                                                                                     6.375 pence                       25,000
                                                                                     6.35 pence                        40,000
                                                                                     6.4 pence                         24,067
                                                                                     6.8 pence                         50,000

 d)   Aggregated information                                                         Total volume: 250,000 Ordinary Shares

                                                                                     Volume weighted average price: 6.274 pence per Ordinary Share

 e)   Date of the transaction                                      14 September 2022, other than purchases referred to in 4 c) of:

                                                                   i)          40,000 Ordinary Shares and 24,067 Ordinary Shares on 15
                                                                   September 2022; and

                                                                   ii)          50,000 Ordinary Shares on 16 September 2022
 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Christopher Hand

 2    Reason for the notification

 a)   Position/status                                              Chairman

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Abingdon Health plc

 b)   LEI                                                          213800XFI4WV3FBILO20

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.025 pence each

      Identification code                                          GB00BLF79J41

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                    Price(s)         Volume(s)
                                                                                    6  pence         500,000
                                                                                    6.9 pence        300,000

 d)   Aggregated information                                                                                          Total volume: 800,000 Ordinary Shares

                                                                                                                      Volume weighted average price: 6.338 pence per Ordinary Share

 e)   Date of the transaction                                      500,000 Ordinary Shares were purchased on 14 September 2022 and 300,000

                                                                 Ordinary Shares were purchased on 16 September 2022.

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEQLFFLKLFBBV